Hematologic Malignancies

Hematologic Malignancies

New data indicates that the order in which people acquired certain somatic mutations influenced several clinical features of myeloproliferative neoplasms.

The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.

A new study suggests that cancer patients do not often request unnecessary and sometimes costly tests or treatments.

A new study finds that childhood cancer survivors are at risk for pituitary hormone deficiencies after radiotherapy treatment to the head.

Despite an association with improved survival, elderly DLBCL patients are less likely to receive standard-of-care chemotherapy with R-CHOP.

Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.

In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.